Efficacy of Badranjboya in Postmenopausal Syndrome: A Randomized Placebo-Controlled Study.

The Unani system of medicine there is no precise description of menopause, it can be discussed under amenorrhea and associated with age of the natural end of menstruation, which is an enrichment to the Unani medical system. More than 90 percent of women could have serious short-term and long-term menopausal syndromes, which include urogenital (vaginal dryness, sexual dysfunction), psychological (stress, anxiety, depression), and vasomotor (hot flashes, sweating) symptoms. Menopausal symptoms have the potential to cause serious mental disease and a low quality of life. One of the Unani medicines isBadranjboya (Melissa officinalisL*.*) in postmenopausal women is effective as it possessesexhilarant,cardiotonic, concoctive, resolvent, carminative, stimulant, and sedative properties.Furthermore, pharmacologically, ithas phytoestrogens, antioxidant, anxiolytic, anti-diabetic, antidepressant, cardioprotective, neuroprotective, anti-inflammatory, and antithyroidal activities.To date, none of the studies has determined the efficacy and safety of Badranjboyain postmenopausal syndrome. Hence, there is a need to conduct a clinical trial to determine the efficacy and safety of Badranjboya in postmenopausal syndrome. The hypothesis of the study  would Badranjboya will be effective in post menopausal sydrome at post intervention.  Diagnosed cases will be randomly allocated either to the test or control group and written informed consent will be obtained. Participants, PG scholars, and analysts will be blinded to the study. Orally, in the test group, Badranjboyafive grams daily will be administered for 8 weeks. In the control group, a placebo will be given. Any adverse reaction to drugs such as abdominal pain, urticaria, itching, nausea, vomiting, headache, fatigue and other unsuspected side effects will be documented. The appropriate tests will be applied to analyse the data. Descriptive statistical analysis will be used in the study. Results on continuous measurements will be presented in mean (SD) and results on the categorical measurements will be presented in number with a 5 percent level of significance and 95 percent confidence interval